NCT02543086 - Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Plasmodium Falciparum Malaria

Interventions

DRUG

KAE609

Study drug

DRUG

Piperaquine Phosphate

Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study

Trial Locations (1)

4006

Novartis Investigative Site, Brisbane